You are here

  • Home
  • Archive
  • Volume 91, Issue 3
  • Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia?

Article Text

Article menu
Download PDFPDF
Letter
Introducing opt-out HIV testing in an acute medical admissions unit: does it improve testing uptake in those with lobar pneumonia?
  1. E Wallis,
  2. J Thornhill,
  3. J Saunders,
  4. C Orkin
  1. Department of Infection and Immunity, Barts Health NHS Trust, London, UK
  1. Correspondence to Dr Chloe Orkin, Department of Infection & Immunity, Barts Health NHS Trust, London E1 1BB, UK; chole.orkin{at}bartshealth.nhs.uk

https://doi.org/10.1136/sextrans-2014-051723

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Current UK National Guidelines for HIV Testing recommend universal HIV testing for all medical admissions where the local diagnosed HIV prevalence exceeds 2 per 1000 population and that those with indicator diseases should always be offered testing in any setting.1 The Royal London Hospital serves a population with a high local HIV prevalence of 6.2/1000,2 four times that of the national prevalence and, therefore, a highly relevant setting for universal HIV testing in the medical admissions unit (MAU). Bacterial pneumonia is a very common clinical indicator condition for HIV, so we used an International Classification of Diseases-10 diagnosis of ‘lobar …

    View Full Text

    Footnotes

    • Funding We have received funding from Gilead Sciences to support the implementation of MAU testing. We have received funding from Bristol-Myers Squibb and Viiv towards other HIV testing initiatives.

    • Competing interests CO has received educational and research grants as well as lecture fees and advisory board fees from BMS, Abbvie, Gilead, Jannsen, Viiv, GSK and Boehringer Ingelheim. JT and JS have received educational grants and or lectureship fees from Gilead, Jannsen and BMS. JS and JT have received educational support from Viiv.

    • Provenance and peer review Not commissioned; externally peer reviewed.